Stocktoria

Immix Biopharma, Inc. IMMX

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2021-12-16

Immix Biopharma, Inc. statistics & valuation

Market cap$710.5M
P / B7.6×
Return on equity-31.3%
Return on capital-31.6%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
202020212022202320242025
Operating margin (%)
202020212022202320242025
Return on equity (%)
-135.50% -62.50% -94.00% -163.10% -31.30% 202020212022202320242025
Shares outstanding
3.4M 13.2M 13.9M 19.9M 28.3M 53.0M 202020212022202320242025
Net debt ($)
202020212022202320242025
Share buybacks ($)
202020212022202320242025
Return on assets (%)
-212.70% -134.00% -55.20% -77.40% -94.20% -28.00% 202020212022202320242025
Free cash flow margin (%)
202020212022202320242025
Debt / equity (×)
202020212022202320242025
EPS ($)
-$0.59 -$0.89 -$0.76 -$0.89 202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020
Return on assets-28.0%-94.2%-77.4%-55.2%-134.0%-212.7%
Return on equity-31.3%-163.1%-94.0%-62.5%-135.5%24.3%
Current ratio10.012.335.3211.7090.010.10

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.